Model-informed COVID-19 vaccine prioritization strategies by age and serostatus
Open accessPublished version of a preprint
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Limited initial supply of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine raises the question of how to prioritize available doses. We used a mathematical model to compare five age-stratified prioritization strategies. A highly effective transmission-blocking vaccine prioritized to adults ages 20 to 49 years minimized cumulative incidence, but mortality and years of life lost were minimized in most scenarios when the vaccine was prioritized to adults greater than 60 years old. Use of individual-level serological tests to redirect doses to seronegative individuals improved the marginal impact of each dose while potentially reducing existing inequities in COVID-19 impact. Although maximum impact prioritization strategies were broadly consistent across countries, transmission rates, vaccination rollout speeds, and estimates of naturally acquired immunity, this framework can be used to compare impacts of prioritization strategies across contexts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Impacts of vaccine prioritization strategies on mortality and infections. (A) Distribution of vaccines for five prioritization strategies: under 20 years, adults 20 to 49 years, adults 20+ years, adults 60+ years, and all ages. (B, C, F, and G) Example simulation curves show [(B) and (C)] percentage of the total population infected over time and [(F) and (G)] cumulative mortality for no vaccines (gray dashed lines) and for five different prioritization strategies [colored lines matching (A)], with [(B) and (F)] 10% and [(C) and (G)] 30% vaccine supply. (D, E, H, and I) Summary curves show percent reductions in [(D) and (E)] infections and [(H) and (I)] deaths in comparison to an unmitigated outbreak for vaccine supplies between 1 and 50% after 365 days of simulation. Squares and diamonds show how the outputs from single simulations [(F) and (G)] correspond to points in summary curves (H). Gray shading indicates the period during which vaccine is being rolled out at 0.2% of total population per day. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. These simulations assume contact patterns and demographics of the United States (38, 53) and an all-or-nothing, transmission-blocking vaccine with 90% vaccine efficacy and R0 = 1.5 (scenario 2) and R0 = 1.15 (scenario 1).](https://figures.cochat.ai/paper-figures/040af1c419fe4105805e757ba6eecdfa/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-1.jpg)
![Fig. 2 Mortality-minimizing vaccine prioritization strategies across reproductive numbers R0 and countries. (A to E) Heatmaps show the prioritization strategies that result in maximum reduction of mortality for varying values of [(A) and (B)] the basic reproductive number R0 and [(C), (D), and (E)] across nine countries, for vaccine supplies between 1 and 50% of the total population, for an all-or-nothing and transmission-blocking vaccine, 90% vaccine efficacy. [(A) and (B)] Contact patterns and demographics of the United States (38, 53). [(C), (D), and (E)] Contact patterns and demographics of POL, Poland; ZAF, South Africa; CHN, China; BRA, Brazil; ZWE, Zimbabwe; ESP, Spain; IND, India; USA, United States of America; and BEL, Belgium, with R0 and rollout speeds as indicated.](https://figures.cochat.ai/paper-figures/3232e6d2c98d4491b422e996e35f7beb/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-2.jpg)
![Fig. 3 Effects of age-dependent vaccine efficacy on the impacts of prioritization strategies. (A) Diagram of hypothetical age-dependent vaccine efficacy shows decrease from 90% baseline efficacy to 50% efficacy among individuals aged 80+ years, beginning at age 60 (dashed line). (B and C) Percent reduction in deaths in comparison with an unmitigated outbreak for transmission-blocking all-or-nothing vaccines with either constant 90% efficacy for all age groups (solid lines) or age-dependent efficacy shown in (A) (dashed lines), covering scenario 1 [0.2% rollout per day, R0 = 1.15; (B)] and scenario 2 [0.2% rollout per day, R0 = 1.5 (C)]. Black dots indicate break points at which prioritized demographic groups have been 70% vaccinated, after which vaccines are distributed without prioritization. Shown are contact patterns and demographics of the United States (38, 53); all-or-nothing and transmission-blocking vaccine.](https://figures.cochat.ai/paper-figures/85e54e74290b4a1b82ec5b49b5f8d03f/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-3.jpg)
![Fig. 4 Effects of existing seropositivity on the impacts of prioritization strategies. (A to C) Percent reductions in (A) infections, (B) deaths, and (C) years of life lost (YLL) for prioritization strategies when existing age-stratified seroprevalence is incorporated [August 2020 estimates for New York City; mean seroprevalence 26.9% (28)]. Plots show reductions for scenario 2 (0.2% rollout per day, R0 = 1.5) when vaccines are given to all individuals (solid lines) or to only seronegatives (dashed lines), inclusive of 96% serotest sensitivity, 99% specificity (54), and approximately 3 months of seroreversion (supplementary materials, materials and methods) (29). Shown are U.S. contact patterns and demographics (38, 53), all-or-nothing and transmission-blocking vaccine with 90% vaccine efficacy. Lower and higher seroprevalence examples are provided in figs. S12 and S13, respectively.](https://figures.cochat.ai/paper-figures/4122f4138dc44271af1ce6fd7d40abb0/model-informed-covid-19-vaccine-prioritization-strategies-by-age-and-serostatus-figure-4.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Vaccination alone is not expected to be able to control the spread of the infection, and a carefully planned vaccination campaign25,26 needs to be coordinated with continued implementation of NPIs27 until sufficient coverage is reached to make the case fatality rate (CFR) similar to that of seasonal influenza.”
From Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-pharmaceutical interventions in Italy (2021) · cites this paper as [25]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2021) · Science · doi:10.1126/science.abf4063 · Cited by 2,656
COVID-19 and Racial/Ethnic Disparities
Webb Hooper, M., Nápoles, A. M., & Pérez-Stable, E. J. (2020) · JAMA · doi:10.1001/jama.2020.8598 · Cited by 2,047 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,759 · cited 1×
“Age-stratified susceptibility values were drawn from literature estimates ( 13 ).”
Sex differences in immune responses that underlie COVID-19 disease outcomes
Takahashi, T., Ellingson, M. K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T., Oh, J. E., Tokuyama, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2700-3 · Cited by 1,459 · cited 1×
“However, other factors correlate with disease outcomes, such as treatment and healthcare access and comorbidities, which may correlate with factors like rural vs urban location, socioeconomic status, sex ( 41, 42 ), and race and ethnicity ( 43 ), that are not accounted for in this study.”
Why does COVID-19 disproportionately affect older people?
Mueller, A. L., McNamara, M. S., & Sinclair, D. A. (2020) · Aging · doi:10.18632/aging.103344 · Cited by 1,128 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China
Zhang, J., Litvinova, M., Liang, Y., Wang, Y., Wang, W., Zhao, S., Wu, Q., Merler, S., Viboud, C., Vespignani, A., et al. (2020) · Science · doi:10.1126/science.abb8001 · Cited by 1,107 · cited 1×
“We evaluated the impact of vaccine prioritization strategies using an age-stratified SEIR model, because age has been shown to be an important correlate of susceptibility ( 12–14 ), seroprevalence ( 12,15 ), severity ( 16–18 ), and mortality ( 19,20 ).”
The Efficacy of Influenza Vaccine in Elderly Persons: A Meta-Analysis and Review of the Literature
Gross, P. A., Hermogenes, A. W., Sacks, H. S., Lau, J., & Levandowski, R. A. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-7-199510010-00008 · Cited by 1,100 · cited 1×
“COVID-19 vaccines may not be equally effective across age groups in preventing infection or transmission, a phenomenon known to affect influenza vaccines ( 23–26 ).”
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940 · cited 2×
“Serostatus itself is an imperfect indicator of protection, and the relationship of prior infection, serostatus, and protection may change over time (10, 29,32,33).”
Govaert, T. M. E. (1994) · JAMA · doi:10.1001/jama.1994.03520210045030 · Cited by 867
Research works printed but not linked: 1
- K. E. Atkinson An Introduction to Numerical Analysis (Wiley 1989) chap. 2 pp. 56–58 second edn.
Cited by
Items 701–777 of 777
Protect or prevent? A practicable framework for the dilemmas of COVID-19 vaccine prioritization
Arghal, R., Rubin, H. N., Bidokhti, S. S., & Sarkar, S. S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0316294
Mathematical modelling for Covid-19
Kumar, R., Saxena, B., Shrivastava, R., & Bhardwaj, R. (2025) · AIP conference proceedings · doi:10.1063/5.0247445 · Cited by 3
Interdisciplinarity and Explanation
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0007
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0013
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0005
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0009
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0008
Systems Biology: Impediments to Integration
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0012
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0001
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.002.0005
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0004
Integrated Understanding for Immunology and Epidemiology
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0011
Explanatory Particularism: Basics and Background
Fagan, M. B. (2025) · Oxford University Press eBooks · doi:10.1093/9780191998874.003.0003
Abraham, S., Dangbé, E., Damakoa, I., & Perasso, A. (2025) · International Journal of Dynamics and Control · doi:10.1007/s40435-025-01688-5
Inferring spreading dynamics of diseases and in neural networks
Dehning, J. (2025) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-11280
Devi, A., & Gupta, P. K. (2025) · Lecture notes in networks and systems · doi:10.1007/978-981-96-1449-3_2
An Analysis of Vaccine Rollout During the COVID-19 Pandemic
Zheng, S. X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2025.au25476
Zhang, X., Araz, Ö. M., & Ertem, Z. (2025) · Health Systems · doi:10.1080/20476965.2025.2533783
“For example, Delta’s high hospitalization rate remains relatively insensitive to increased vaccination, while Omicron’s high transmissibility reduces the benefit of excessive (Bubar et al., 2021).”
Li, A., Wang, T., Zhang, B., Hou, X., Sun, P., Wang, H., Xu, H., Tan, M. J. A., Gong, X., Wu, J., et al. (2025) · Biomolecules · doi:10.3390/biom15081172
McCombs, A., & Kadelka, C. (2021) · The Conversation · doi:10.64628/aai.srfvq946d
Torres-Florez, S., Anato, J. L. F., He, J. H., Portilla, V. G., Wu, Y., Maheu‐Giroux, M., Racine, É., & Wagner, C. E. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013207
“…vaccine hesitancy into model-based policy evaluation efforts, as has been done in some models for the distribution of the COVID-19 vaccine [15,16], to ensure that projections accurately capture the uncertainty in achievable vaccine coverage due to reduced uptake arising from individual…”
González‐Parra, G., Luebben, G., Villanueva, R. J., Navarro-González, F. J., & Bhakta, B. (2025) · Mathematics and Computers in Simulation · doi:10.1016/j.matcom.2025.10.015 · Cited by 1
Determine Vaccination Priority in a Population of Partially Overlapping Groups
Gou, W., Peng, X., Li, J., Lou, J., Zhang, F., & Jin, Z. (2025) · CSIAM transactions on life sciences. · doi:10.4208/csiam-ls.so-2025-0011
Patón, M., Hantouche, M., Hosani, F. I. A., Sadani, A., Rodríguez, J., & Abuyadek, R. M. (2025) · Infectious Disease Modelling · doi:10.1016/j.idm.2025.10.006
The dynamical behavior of an almost periodic sveir warning model in a patchy environment
Wang, B.-G., Ma, X., & Wang, Y. (2025) · Acta Mathematica Scientia · doi:10.1007/s10473-026-0123-4
Garcia, Y., Díaz‐Infante, S., & Minjárez‐Sosa, J. A. (2025) · Computational and Applied Mathematics · doi:10.1007/s40314-025-03498-z
“…temperature-driven degradation; coverage becomes endogenous Stochastic optimal control with deliv-eryandtemperatureuncertainty;time-dependentepidemic–inventorycou-pling uncertainty in transmission alters outcomes (Bubar et al. 2021; Dey et al. 2024; Acuña-Zegarra et al. 2021; Garcia et al. 2025).”
Aruffo, E., Yuan, P., Tan, Y., Gatov, E., Moyles, I. R., Bélair, J., Watmough, J., Collier, S., Arino, J., & Zhu, H. (2022) · Figshare · doi:10.6084/m9.figshare.20324715
Additional file 3 of Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
Rasambainarivo, F., Ramiadantsoa, T., Raherinandrasana, A. H., Randrianarisoa, S., Rice, B. L., Evans, M., Roche, B., Randriatsarafara, F. M., Wesolowski, A., & Metcalf, J. C. (2022) · Figshare · doi:10.6084/m9.figshare.19586866
Bilgin, G. M., Lokuge, K., Jabbie, E., Munira, S. L., & Glass, K. (2023) · Figshare · doi:10.6084/m9.figshare.24792219
Additional file 1 of Inequality in the distribution of Covid-19 vaccine: a systematic review
Bayati, M., Noroozi, R., Ghanbari‐Jahromi, M., & Jalali, F. S. (2022) · Figshare · doi:10.6084/m9.figshare.20745413
Li, M., Zu, J., Zhang, Y., Ma, L., Shen, M., Li, Z., & 纪泛扑 (2022) · Figshare · doi:10.6084/m9.figshare.19367708
Additional file 2 of Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
Rasambainarivo, F., Ramiadantsoa, T., Raherinandrasana, A. H., Randrianarisoa, S., Rice, B. L., Evans, M., Roche, B., Randriatsarafara, F. M., Wesolowski, A., & Metcalf, J. C. (2022) · Figshare · doi:10.6084/m9.figshare.19586863
Acuña‐Zegarra, M. A., Santana-Cibrian, M., Hernandez-Vela, C. E. R., Mena, R. H., & Velasco-Hernández, J. X. (2022) · medRxiv · doi:10.1101/2022.04.29.22274465
Additional file 1 of Prioritizing COVID-19 vaccination efforts and dose allocation within Madagascar
Rasambainarivo, F., Ramiadantsoa, T., Raherinandrasana, A. H., Randrianarisoa, S., Rice, B. L., Evans, M., Roche, B., Randriatsarafara, F. M., Wesolowski, A., & Metcalf, J. C. (2022) · Figshare · doi:10.6084/m9.figshare.19586857
Ye, Y., Huang, L., Wang, J., Chuang, Y.-C., & Pan, L. (2023) · Figshare · doi:10.6084/m9.figshare.22602145
Li, M., Zu, J., Zhang, Y., Ma, L., Shen, M., Li, Z., & 纪泛扑 (2022) · Figshare · doi:10.6084/m9.figshare.19367711
WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply
WHO SAGE Working Group on COVID-19 Vaccines (2020) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · Cited by 63
Vaccines: Populations, Individuals and Models
Joshi, K. D. (2023) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
When Should Fractional-Dose Vaccines Be Used?
de Véricourt, F., Gallien, J., & Ghosh, N. (2025) · Manufacturing & Service Operations Management · doi:10.1287/msom.2024.1332 · Cited by 1
Liang, H., Khairunnasa, F., & Yuan, H. (2026) · Vaccine X · doi:10.1016/j.jvacx.2025.100774
Pontes, M. M. C., de Sá, M. C. D. N. P., & 2024-05-06 (2024) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Domma, F., Soraci, L., Paparazzo, E., Amerise, I. L., Aceto, M. A., Cassano, T. S., Bellizzi, D., Cosimo, S. C., Morelli, F., Corsonello, A., et al. (2026) · Viruses · doi:10.3390/v18010109
“Extensive clinical and real-world evidence has demonstrated that timely and widespread vaccination not only decreased infection rates but also mitigated the impact of emerging variants [15–17].”
Ko, Y., Seo, Y., Park, J. J., Kim, E. Y., Moon, J. Y., Kim, T., Eom, J. S., Oh, H. S., Kim, A., Kim, J. Y., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0315072
“Prioritizing vaccination for the elderly, who have higher severity/ fatality rates, was the best strategy for minimizing deaths when social distancing measures were in place to reduce the effective reproduction number to approximately one [35,36].”
Age-structured dynamics and susceptibility in the face of infection and vaccinationPreprint
Li, R., Aragaw, M., Maeda, J. M., Metcalf, C. J. E., Bjørnstad, O. N., & Stenseth, N. C. (2026) · medRxiv · doi:10.64898/2026.02.10.26345956
A new take on optimal vaccine prioritization: when age-based strategy is efficient?
Gonçalves, M., Fierens, P. I., & Leandro Chaves, R. E. G. O. (2026) · International Journal of Data Science and Analytics · doi:10.1007/s41060-026-01053-5
Targeted vaccination in a pandemic: a system dynamics analysis of age, dose, and timing strategies
Singh, R., Amit, R. K., & Mohan, T. V. K. (2026) · Journal of Simulation · doi:10.1080/17477778.2026.2639505
Simulering av skyddsåtgärders effekt på COVID-19 spridning med hjälp av verkligt kontaktnätverk
Wuori, M. (2021) · Aaltodoc (Aalto University)
Gradient Guided Parameter Space Sampling for Knowledge Discovery With Limited Budgets
Antón, J. R., Sapino, M. L., & Candan, K. S. (2026) · IEEE Access · doi:10.1109/access.2026.3680318
Cot, C. (2021) · theses.fr (ABES) · doi:10.70675/32baf057zb898z40b8zbf61z75835e8c639c · Cited by 1
Modéliser la propagation et le contrôle du SARS-CoV-2 en France
Kiem, C. T. (2022) · theses.fr (ABES) · doi:10.70675/ee2d278bz060dz47c1za2c7zde12caebb50b
Changing COVID-19 vaccine eligibility could reshape disease burden for allPreprint
Larsen, S. L., Martinez, P. P., & Mahmud, A. S. (2026) · medRxiv · doi:10.64898/2026.04.27.26351870
Modeling individual self-protective behavior during epidemics
Yu, G., Garee, M. J., Ventresca, M., & Yih, Y. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014252
Kiang, M. V., & Wrigley‐Field, E. (2021) · OSF Preprints (OSF Preprints)
Li, T., Hu, Y., Wang, X. J., Li, X., Jia, Y., & Yang, L. (2026) · Nonlinear Dynamics · doi:10.1007/s11071-026-12619-0
“Early responses typically include risk communication and data sharing, intensified surveillance of incidence and growth rates [4, 5], case isolation and contact management [6, 7], restrictions on mass gatherings [8, 10], and vaccination and targeted protection of high-risk groups [11, 12].”
Ma, Y., Ning, Y., Guo, J., Xu, S., Luo, Y., Li, J., Lei, L., He, L., Wang, T., Yu, H., et al. (2026) · BMC Public Health · doi:10.1186/s12889-026-27891-3
“Therefore, while continuing to promote vaccinations for the elderly, it is also necessary to strengthen community health education to popularize the knowledge related to the prevention of major respiratory infectious diseases such as COVID-19 [22].”
Analytics for Resource Allocation in Pandemic Management
Haferkamp, J., Bicher, M., Ghasemi, P., Ulmer, M. W., Popper, N., & Ehmke, J. F. (2026) · INFORMS Journal on Applied Analytics · doi:10.1287/inte.2025.0275
Modeling the Distribution and Impact of Immunity to COVID-19 in Populations
Rumpler, É. (2026) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Efficacy versus coverage: population-level impacts of vaccination schemes
Lin, L., & Stone, L. (2026) · Infectious Disease Modelling · doi:10.1016/j.idm.2026.07.001
“Although this is a simplifying assumption, it is commonly used and remains appropriate in many studies (Bubar et al., 2021; Gallagher et al., 2021; Gavish & Katriel, 2022).”
InfluentialFeng, Z., Day, T., & Glasser, J. W. (2026) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2026.112531
Delay distributions limit the identifiability of rapid variations in epidemicsPreprint
Tang, J., Wilder, B., & Rosenfeld, R. (2026) · medRxiv · doi:10.64898/2026.07.23.26358599
Bouramtane, K., Kharraja, S., Riffi, J., Beqqali, O. E., & Boujraf, S. (2026) · Expert Systems with Applications · doi:10.1016/j.eswa.2026.133816
Modeling and optimizing intervention policies
Lazebnik, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-44-355525-1.00016-3
(2026) · Elsevier eBooks · doi:10.1016/b978-0-44-355525-1.00020-5
Osorio, A. D. S., Polo, J. E. R., Cansaya, A. A. C., & Alva, J. (2026) · LACCEI International Multi-Conference for Engineering, Education and Technology (LACCEI) · doi:10.18687/laccei2026.1.1.1453
Peers matter more: Age-based herding in COVID-19 vaccination
Epstein, G. S., Heizler, O., & Israeli, O. (2026) · Journal of Economic Behavior & Organization · doi:10.1016/j.jebo.2026.107711
Imperfect vaccination and coupled epidemic dynamics in age-structured multiplex networks
Qian, Y. H., Wang, N.-N., Zhao, D., & Xia, C. (2026) · Chaos An Interdisciplinary Journal of Nonlinear Science · doi:10.1063/5.0347760
Loo, S. L., Nande, A., Truelove, S., & Hill, A. L. (2026) · medRxiv · doi:10.64898/2026.08.18.26360623
Hoang, V., & Nguyen, C. (2026) · SAGE Open · doi:10.1177/21582440261484694
The Hidden Challenge: Asymptomatic Carriers in Epidemics with Imperfect Vaccination
Jin, W., Gao, Y., Tan, Q., Liu, M., Liu, J., & Shi, B. (2025) · IEEE/WIC/ACM International Conference on Web Intelligence and Intelligent Agent Technology (WI-IAT) · doi:10.1109/wi-iat67162.2025.00119
“By capturing transmission mechanisms mathematically, such models enable researchers and policymakers to anticipate outbreak trajectories, evaluate interventions, and support evidence-based decisions [1], [2].”
Tu, Y., Meng, X., & Zhu, H. (2026) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2026.110823
Monari, F. N. (2026) · Journal of Innovative Applied Mathematics and Computational Sciences · doi:10.58205/jiamcs.v6i1.1997
Xing, Y., Zhang, J., Haoliang, C., Yang, Z., Wang, Q., Qin, L., Wang, Z., & Jia, Z. (2026) · arXiv (Cornell University) · doi:10.48550/arxiv.2610.13567
Prioritising Vaccine Distribution Strategies Using Multi-Criteria Decision-Making
Şimşek, A., & Şimşek, A. B. (2026) · IGI Global eBooks · doi:10.4018/979-8-2600-4881-8.ch004
Asim, M., Nasratullah, O. K., Ishfaq, H., Basit, A., & Shcheglov, B. O. (2026) · Clinical and Fundamental Medicine · doi:10.24866/3033-5485/2026-3/47-67
Optimal Control and Cost‐Effectiveness in a Dynamic Vaccination Model for COVID‐19
Adda, R. B., & Adda, C. (2026) · International Journal of Mathematics and Mathematical Sciences · doi:10.1155/ijmm/2034556
Metadata
- Authors
- Bubar, K. M., Reinholt, K., Kissler, S. M., Lipsitch, M., Cobey, S., Grad, Y. H., & Larremore, D. B.
- Affiliations
- University of Colorado Boulder (US)
- Harvard University (US)
- University of Chicago (US)
- Corresponding author
- Bubar, Kate M.
- Larremore, Daniel B.
- ORCID
- Venue
- Science
- Published
- 2021-02-26
- Volume
- 371
- Issue
- 6532
- Pages
- 916-921
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7963218
- OpenAlex
- W3123021790
- Cited by
- 775
- References
- 45
- Citations by year
- 2026: 32 · 2025: 56 · 2024: 87 · 2023: 109 · 2022: 222 · 2021: 261
- FWCI
- 65.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Knowledge@UChicago (University of Chicago) (submittedVersion, cc-by-nc-nd)
- PubMed Central (submittedVersion, cc-by-nc-nd)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- ImmPort
- University of Chicago (cc-by)
- Funders
- National Institutes of Health (3U24GM132013-02S2)
- Morris-Singer Fund
- Topics
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine prioritization, SARS-CoV-2, serostatus, serological testing, transmission-blocking vaccine, vaccine inequity, cumulative incidence, mortality, years of life lost, naturally acquired immunity, vaccine supply
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.